Vedolizumab Achieved Clinical and Histologic Remission in a Patient with Lung Cancer Who Had a Steroid-Refractory Upper Gastrointestinal Injury Due to Nivolumab Treatment

Vedolizumab Achieved Clinical and Histologic Remission in a Patient with Lung Cancer Who Had a Steroid-Refractory Upper Gastrointestinal Injury Due to Nivolumab Treatment

Immune checkpoint inhibitors (ICIs) have emerged as a novel therapeutic class for various malignancies. Their immune upregulation promotes significant anti-tumor effect, but simultaneously, can also result in treatment-limiting immune-related adverse events (irAEs). The data on upper gastrointestina...

Full description

Bibliographic Details
Main Authors: Cynthia Nguyen Tran, Hamzah Abu-Sbeih, Wenyi Luo, Yang Lu, Yinghong Wang
Format: Article
Language:English
Published: Innovative Healthcare Institute 2019-05-01
Series:Journal of Immunotherapy and Precision Oncology
Subjects:
adverse event
gastritis
gastrointestinal tract
immune checkpoint inhibitors
pancreatitis
vedolizumab
Online Access:https://jipo.org/doi/pdf/10.4103/JIPO.JIPO_18_18

Internet

https://jipo.org/doi/pdf/10.4103/JIPO.JIPO_18_18

Similar Items